Navigation Links
At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients

EXTON, Pa., Sept. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one month post-launch of Algeta/Bayer HealthCare's Xofigo in the United States, approximately one quarter of surveyed U.S. medical oncologists indicated that they have prescribed Xofigo. According to the first wave of the LaunchTrends® Xofigo report series, nearly half of current non-prescribers stated that they would prescribe Xofigo in the next four to six months. Notably, the majority of current non-prescribers indicated that they would prescribe Xofigo to both their docetaxel-naive and docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC) patients.


The report also finds that over half of surveyed medical oncologists reported high favorability toward Xofigo, and a majority of respondents indicated a high level of interest in Xofigo. For docetaxel-naive mCRPC, the highest proportion of surveyed medical oncologists indicated that the bone-targeted mechanism of action of Xofigo and its safety profile are among the main advantages of the agent. For docetaxel-pretreated mCRPC, the main perceived advantages of Xofigo over Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga and Medivation/Astellas Pharma's Xtandi lie in Xofigo's limited and fixed treatment duration and the fact that it is an efficacious bone-targeted agent, according to surveyed medical oncologists.

"Surveyed medical oncologists cited the need to refer patients to a licensed nuclear medicine facility as one of the main disadvantages of Xofigo compared to other agents used to treat docetaxel-naive and docetaxel-pretreated mCRPC," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "We also find that just over half of Xofigo non-prescribers indicated that they are aware of the nearest location licensed for Xofigo administration."

LaunchTrends: Xofigo (US) is a three-wave syndicated report series designed to track the uptake of Xofigo at one month, six months and one year following Xofigo's commercial availability, based upon primary research with U.S. medical oncologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. For this first wave of research, BioTrends surveyed 75 U.S. medical oncologists and conducted qualitative interviews with 13 U.S. medical oncologists in July 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
2. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
3. Inaugural National Mobility Awareness Month Commences in May Saluting the More than 18 Million with Disabilities
4. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
5. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
6. Herborium Group Reports Record 6 Month Revenues
7. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
8. Regional Medical Center at Memphis Completes Rapid Six-Month Implementation of Comprehensive Perioperative and Anesthesia Solution from Surgical Information Systems
9. Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
10. Comprehensive Care Corporation Announces Profitable Six Month Financial Results
11. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):